Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.

Abstract

IMPORTANCE:

The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non-small cell lung cancer (NSCLC).

OBJECTIVE:

To evaluate the effect of PORT using modern techniques on survival and safety in patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy.

DESIGN, SETTING, AND PARTICIPANTS:

The PORT-C randomized clinical trial was conducted in 394 patients with pIIIA-N2 NSCLC treated with complete resection and 4 cycles of platinum-based chemotherapy between January 2009 and December 2017. Data were analyzed between March 2019 and December 2020.

INTERVENTIONS:

Patients were randomized equally into the PORT arm (n = 202) or the observation arm (n = 192). The total dose of PORT was 50 Gy.

MAIN OUTCOMES AND MEASURES:

The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival, and toxic effects.

RESULTS:

In total, 394 patients were enrolled and 364 were eligible, with a median (range) age of 55 (25-70) years. There were 202 (55.5%) male and 162 (44.5%) female patients. The median follow-up was 46.0 (95% CI, 41.9-51.4) months, and 230 DFS events were reported. There were 184 patients in the PORT arm and 180 patients in the observation arm. The 3-year DFS rates were 40.5% with PORT vs 32.7% with observation (median, 22.1 vs 18.6 months), and the difference in DFS was not statistically significant without adjustment (hazard ratio [HR], 0.84; 95% CI, 0.65-1.09; P = .20), though it was significant with preplanned yet exploratory analysis (stratified analysis by the number of detected lymph nodes and positive lymph nodes, HR, 0.75; log-rank P = .04). The 3-year OS rates were 78.3% vs 82.8% (HR, 1.02; P = .93), and LRFS was 66.5% vs 59.7% (HR, 0.71; 95% CI, 0.51-0.97; P = .03), respectively. For 310 per-protocol patients (140 with PORT and 170 with observation), PORT significantly improved DFS (42.8% vs 30.6%; HR, 0.75; 95% CI, 0.57-1.00; P = .05) but not OS (HR, 0.83; 95% CI, 0.53-1.30; P = .41). The 3-year local recurrence only rates were 9.5% and 18.3% in the 2 arms, respectively (Fine-Gray HR, 0.55; Gray test P = .04). No radiotherapy-related grade 4 or 5 adverse event was observed.

CONCLUSIONS AND RELEVANCE:

In this phase 3 randomized clinical trial of patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy, PORT did not improve DFS. Further studies exploring patients who might best benefit from PORT are needed.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT00880971.

• Authors: Zhouguang Hui, Yu Men, Chen Hu, Jingjing Kang, Xin Sun, Nan Bi, Zongmei Zhou, Jun Liang, Jima Lv, Qinfu Feng, Zefen Xiao, Dongfu Chen, Yan Wang, Junling Li, Jie Wang, Shugeng Gao, Luhua Wang, Jie He
• Journal: JAMA oncology (JAMA Oncol) Vol. 7 Issue 8 Pg. 1178-1185 (Aug 01 2021) ISSN: 2374-2445 [Electronic] United States
• PMID: 34165501 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial)

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy, radiotherapy, surgery)
• Chemotherapy, Adjuvant
• Female
• Humans
• Lung Neoplasms (drug therapy, radiotherapy, surgery)
• Male
• Neoplasm Staging
• Radiotherapy, Adjuvant
• Retrospective Studies